1. Home
  2. NKSH vs ACRS Comparison

NKSH vs ACRS Comparison

Compare NKSH & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NKSH
  • ACRS
  • Stock Information
  • Founded
  • NKSH 1891
  • ACRS 2012
  • Country
  • NKSH United States
  • ACRS United States
  • Employees
  • NKSH N/A
  • ACRS N/A
  • Industry
  • NKSH Major Banks
  • ACRS Biotechnology: Pharmaceutical Preparations
  • Sector
  • NKSH Finance
  • ACRS Health Care
  • Exchange
  • NKSH Nasdaq
  • ACRS Nasdaq
  • Market Cap
  • NKSH 163.0M
  • ACRS 165.7M
  • IPO Year
  • NKSH N/A
  • ACRS 2015
  • Fundamental
  • Price
  • NKSH $29.31
  • ACRS $1.47
  • Analyst Decision
  • NKSH Strong Buy
  • ACRS Strong Buy
  • Analyst Count
  • NKSH 1
  • ACRS 8
  • Target Price
  • NKSH $38.00
  • ACRS $9.71
  • AVG Volume (30 Days)
  • NKSH 18.4K
  • ACRS 1.3M
  • Earning Date
  • NKSH 08-13-2025
  • ACRS 08-06-2025
  • Dividend Yield
  • NKSH 5.22%
  • ACRS N/A
  • EPS Growth
  • NKSH N/A
  • ACRS N/A
  • EPS
  • NKSH 1.38
  • ACRS N/A
  • Revenue
  • NKSH $46,211,000.00
  • ACRS $17,777,000.00
  • Revenue This Year
  • NKSH N/A
  • ACRS N/A
  • Revenue Next Year
  • NKSH $5.93
  • ACRS $11.77
  • P/E Ratio
  • NKSH $20.91
  • ACRS N/A
  • Revenue Growth
  • NKSH 2.21
  • ACRS N/A
  • 52 Week Low
  • NKSH $23.75
  • ACRS $1.05
  • 52 Week High
  • NKSH $33.37
  • ACRS $5.17
  • Technical
  • Relative Strength Index (RSI)
  • NKSH 70.94
  • ACRS 51.06
  • Support Level
  • NKSH $27.01
  • ACRS $1.38
  • Resistance Level
  • NKSH $27.88
  • ACRS $1.52
  • Average True Range (ATR)
  • NKSH 0.76
  • ACRS 0.10
  • MACD
  • NKSH 0.33
  • ACRS -0.01
  • Stochastic Oscillator
  • NKSH 92.51
  • ACRS 39.10

About NKSH National Bankshares Inc.

National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Share on Social Networks: